First Choice Neurology

M. Joshua Hasbani, MD, PhD

M. Joshua Hasbani, MD, PhD

M. Joshua Hasbani, MD, PhDM. Joshua Hasbani, MD, PhD, is a neurologist in private practice in Boca Raton, Florida, and New Haven, Connecticut. He received his MD and PhD from Washington University School of Medicine in St. Louis, Missouri. He completed his residency in neurology at the Hospital of the University of Pennsylvania in Philadelphia, followed by a fellowship in clinical neurophysiology at Yale New Haven Hospital in Connecticut. He is board-certified in neurology, clinical neurophysiology, and headache medicine.

Dr. Hasbani is a member of the American Academy of Neurology, American Headache Society, and the American Association of Neuromuscular & Electrodiagnostic Medicine. He is a fellow and board member of the International Academy of Independent Medical Evaluators.

He is a Primary Investigator for several clinical trials, including Alzheimer disease, migraine, and spasticity studies. He has authored or coauthored articles published in peer-reviewed journals such as Neurology, Multiple Sclerosis and Related Disorders, and Case Reports in Neurology.

Dr. Hasbani practices monthly in Boca Raton, Florida. Visit his Connecticut neurology practice website at hasbanineurology.com(opens in new tab). 

Schedule Appointment

Specialties
ALS, Alzheimer's Disease, Back Pain, Botox Injections, Botulinum Toxins, Carpal Tunnel Syndrome, Concussion, Dementia, Dizziness, Electromyography, Epilepsy, Facial Pain, Fibromyalgia, Headaches/Migraines, Movement Disorders, Multiple Sclerosis, Myasthenia Gravis, Neck and Back Pain, Neurology, Neuromuscular Disorders, Neuropathy, Parkinson's Disease, Seizures, Spasticity, Spine Disorders, Stroke, Traumatic Brain Injury, Tremors, and Vertigo.

Board Certifications
American Board of Psychiatry and Neurology
Clinical Neurophysiology
Headache Medicine

Medical Interests
Traumatic Brain Injury and Concussion

Education
Johns Hopkins University - BA in Biology, 1994
Washington University School of Medicine in St. Louis - MD, PhD, 2001

Residency 
Neurology Residency at the Hospital of the University of Pennsylvania, 2005

Fellowships
Clinical Neurophysiology at Yale School of Medicine, 2006

Memberships
American Academy of Neurology
American Headache Society
American Academy of Neurophysiology and Electrodiagnostic Medicine
International Association of Independent Medical Examiners

Research & Clinical Trials

Publications and Original Papers:

Gaglio, T., Saredi A., Bingham J.B., Hasbani M.J., Gill S.R., Schroer T.A., Compton D.A.: Opposing motor activities are required for the organization of the mammalian mitotic spindle pole. Journal of Cell Biology 135:399-414, 1996.

Faddis B.T., Hasbani M.J., Goldberg M.P.: Roles of calpain in hypoxic-ischemic neuronal injury. In: Pharmacology of Cerebral Ischemia, 1996 (Krieglstein J, Oberphichler-Schwenk H eds), Stuttgart: Wissenschaftliche Verlagsgesellschaft mbH.

Faddis B.T., Hasbani M.J., Goldberg M.P.: Calpain activation contributes to dendritic remodeling
after brief excitotoxic injury in vitro. The Journal of Neuroscience 17:951-959, 1997.

Hasbani M.J., Hyrc K.L., Faddis B.T., Romano C., Goldberg M.P.: Distinct roles for sodium, chloride, and calcium in excitotoxic dendritic injury and recovery. Experimental Neurology 154(1):241-258, 1998.

Valetti C., Wetzel D.M., Schrader M., Hasbani M.J., Gill S.R., Kreis T.E., Schroer T.A.: Role of dynactin in endocytic traffic: Effects of dynamitin overexpression and colocalization with CLIP-170. Molecular Biology of the Cell 10:4107-4120, 1999.

Gutmann D.H., Zhang Y., Hasbani M.J., Goldberg M.P., Plank T.L., Henske E.P.: Expression of
the tuberous sclerosis complex (TSC) gene products, hamartin and tuberin, in central nervous system tissue. Acta Neuropathologica 99:223-230, 2000.

Hasbani M.J., Underhill S.M. deErausquin G.A., Goldberg M.P.: Synapse loss and regeneration: a
mechanism for functional decline and recovery after cerebral ischemia? The Neuroscientist 6(2):108-117, 2000.

Hasbani M.J., Schlief M.L., Fisher D.A., Goldberg M.P.: Dendritic spines which disappear during
glutamate receptor activation re-emerge at original sites of synaptic contact. The Journal of Neuroscience 21(7):2393-2403, 2001.

Hasbani M.J., Viquez N.M., Goldberg M.P.: NMDA receptors mediate hypoxic spine loss in cultured neurons. Neuroreport 12(12):2731-2735, 2001.

Hasbani M.J., Sansing L., Perrone J., Asbury A.K., and Bird, S.J. Encephalopathy and peripheral neuropathy following diethylene glycol ingestion. Neurology 12;64(7):1273-5, 2005.

Ances BM, Dalmau JO, Tsai J, Hasbani MJ, Galetta SL. Downbeating nystagmus and muscle spasms in a patient with glutamic-acid decarboxylase antibodies. Am J Ophthalmol 140(1):142-4, 2005.

Hannah-Shmouni F, Matiello M, Russell DS, Hasbani MJ. Teaching Video Neuroimages: spasmodic dysphonia preceding idiopathic parkinsonism. Neurology Feb 11;82(6);e55, 2014.

Guarnaccia JB, Cabot A, Garten LL, Napoli S, Hasbani MJ. Teriflunomide levels in women whose male sexual partner is on teriflunomide for relapsing multiple sclerosis. Mult Scler Relat Disord. 2022 Jan;57:103347. doi:10.1016/j.msard.2021.103347. Epub 2021 Oct 28. PMID: 35158456.

Mastropaolo M, Hasbani M, J: Small Fiber Neuropathy Triggered by COVID-19 Vaccination: Association with FGFR3 Autoantibodies and Improvement during Intravenous Immunoglobulin Treatment. Case Rep Neurol 2023:6-10. doi:10.1159/000528566

Mastropaolo, M, Schindler, J.L., Hasbani, M.J.: Reversible Cerebral Vasoconstriction Syndromes: Presentation, Diagnosis, and Treatment of a Complex Neurovascular Disorder. Practical Neurology (US) 2024;23(5):43-47.

Selected Abstracts:

Hasbani M.J., Dugan L.L., deErausquin G.A., Goldberg M.P.: Carboxyfullerene protects neurons from NMDA-induced dendritic injury. Society for Neuroscience Abstracts 24(1):214, 1998.

Goldberg M.P., Hasbani M.J., Tekkok S.B.: Effects of oxygen-glucose deprivation on cortical axons in vitro. Society for Neuroscience Abstracts 25(1):577, 1999.

Guarnaccia JB, Cabot A, Garten L, Napoli SQ, Hasbani MJ. Teriflunomide Levels in Women Whose Male Sexual Partner is on Teriflunomide for Relapsing Multiple Sclerosis. Actrims 2019 Forum. February 28, 2019.

Book Chapter:

Underhill SM, Baltan Tekkök S, Hasbani MJ, Goldberg MP. “Cellular mechanisms of white matter ischemia - what can we learn from culture models?” Cerebrovascular Disease: 22nd Princeton Conference (Chan, PH, editor), 2002.

Research Experience:

Principal Investigator

“A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport®) in Comparison With OnabotulinumtoxinA (Botox®) When Treating Adults With Upper Limb Spasticity” Ipsen, 2021-2025

“A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimer's Disease (TargetTau-1) Protocol number: CN008-0003” Bristol-Myers-Squibb, 2024-Present

“BHV2100-201: Phase II Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging Trial of BHV-2100 for the Acute Treatment of Migraine” Biohaven, 2024-2025

“A Phase III, Randomized, Double-blind, Placebo-controlled, Multicentre, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants” Ipsen, 2025-Present

“A Phase III, Randomized, Double-blind, Placebo-controlled, Multicentre, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants” Ipsen, 2025-Present

“A Randomized, Double-blind, Parallel-group Study to Compare Pharmacokinetics, Pharmacodynamics, Clinical Effects, and Safety between ABP 692 and Ocrevus® (Ocrelizumab) in Subjects with Relapsing-remitting Multiple Sclerosis” Amgen, 2025-Present

“Interventional, open-label trial, investigating the effectiveness of eptinezumab in participants with migraine and previous inadequate response to CGRP-targeting therapies” Lundbeck, 2025-Present

“A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial with extension period to evaluate the efficacy and safety of Xeomin® injections for the prevention of chronic migraine.” Merz, 2025-Present

“A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial with extension period to evaluate the efficacy and safety of Xeomin® injections for the prevention of episodic migraine.” Merz, 2025-Present

“A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial to evaluate the efficacy of Rimegepant in the acute treatment of Pediatric and Adolescent Migraine”. Pfizer C495009. 2026 – Present.

Sub Investigator

“An Open-Label, Non-Randomized Study to Evaluate the Feasibility of [18F]Florbetapir Positron Emission Tomography (PET) for Assessment of Demyelination in Patients With Relapsing Remitting Multiple Sclerosis” 2013-2014

“Longitudinal Evaluation of [18F]GTP1 as a PET Radioligand for Imaging Tau in the Brain of Patients With Prodromal, Mild, and Moderate Alzheimer's Disease Compared to Healthy Volunteers” 2015-2016

“Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability and Efficacy of BIIB092 in Subjects with Mild Cognitive Impairment due to Alzheimer's Disease or with Mild Alzheimer's Disease” 2018-Present

“SV2A PET Study to Evaluate the Effect of CT1812 Treatment in subjects with AD (COG-RX)” 2018- Present

“Clinical Evaluation of a radioactive compound in PET Scan” 2019-2020

“A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Efficacy, and Safety Study of MTAU9937A in Patients with Prodromal to Mild Alzheimer's Disease” 2018-2019.

“A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study with an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease” 2019-Present

“AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment with BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects with Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial)” 2020

“Alzheimer's Disease Neuroimaging Initiative 4 (ADNI-4)” 2023

“Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (aducanumab) in Subjects with Alzheimer’s disease Who Had Previously Participated in the Aducanumab Studies” 2020-Present

“COG0203: A Randomized, Double-Blind Placebo-Controlled, Parallel-Group Trial to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease over 18 Months (START)” Cognition Therapeutics, 2020-Present

“Protocol 63733657ALZ2002 Phase 2 A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Assess the Efficacy and Safety of JNJ-63733657, an Anti-tau Monoclonal Antibody, in Participants with Early Alzheimer's Disease” Janssen, 2021-Present

“A Phase 2, Placebo-Controlled, Double-Blind, Parallel-Group, Dose -Finding Study to Evaluate Safety, Tolerability, and Biomarker Efficacy of E2814 With Concurrent Lecanemab Treatment in Subjects With Early Alzheimer's Disease” Eisai, 2024-Present

“DIAN TU 001: A Phase II/III Randomized, Double-blind, Placebo-Controlled, Cognitive Endpoint, Multi-Center Study of Potential Disease Modifying Therapies in Individuals at Risk for and with Dominantly Inherited Alzheimer's Disease” IQVIA, 2024-Present

Accepts New Patients
Yes

Insurance 
List of insurance plans accepted

Languages
English

Location
9970 Central Park Boulevard N, Suite 207
Boca Raton, FL 33428
Phone: (561) 482-1027
Fax: (561) 482-1028

Hours
The first Thursday, Friday, and Saturday
of each month from 8:30 AM–5:00 PM

 

M. Joshua Hasbani, MD, PhD, is a board-certified neurologist in Boca Raton, Florida. Call the office at (561) 482-1027 to schedule an appointment.

Translate »